DGAP-News

ERYTECH Completes Patient Enrollment in Phase 2 Trial of eryaspase (GRASPA(R)) for Pancreatic Cancer - Seite 3

operational manufacturing site in Lyon (France), and at a site for clinical
production in Philadelphia (USA). ERYTECH has entered into licensing and
distribution partnership agreements for eryaspase for ALL and AML in Europe
with Orphan Europe (Recordati Group), and for ALL in Israel with TEVA,
which will market the product under the GRASPA(R) brand name.

ERYTECH is listed on Euronext regulated market in Paris (ISIN code:
FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC Pharma &
Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next
Biotech indexes. ERYTECH is also listed in the U.S. under an ADR level 1
program (OTC, ticker EYRYY).

CONTACTS

ERYTECH                    The Ruth Group            NewCap
Gil Beyen                  Lee Roth                  Julien Perez
Chairman and CEO           Investor relations        Investor relations
Eric Soyer                 Kirsten Thomas            Nicolas Merigeau
CFO and COO                Media relations           Media relations
[phone]          [phone]           [phone]
[e-mail]      [e-mail]    [e-mail]
                           [phone]
                           [e-mail]

Forward-looking information

This document may contain forward-looking statements and estimates with
respect to the financial position, results of operations, business
strategy, plans, objectives and anticipated future performance of ERYTECH
and of the market in which it operates. Certain of these statements,
forecasts and estimates can be recognized by the use of words such as,
without limitation, "believes", "anticipates", "expects", "intends",
"plans", "seeks", "estimates", "may", "will" and "continue" and similar
expressions. They include all matters that are not historical facts. Such
statements, forecasts and estimates are based on various assumptions and
assessments of known and unknown risks, uncertainties and other factors,
which were deemed reasonable when made but may or may not prove to be
correct. Actual events are difficult to predict and may depend upon factors
that are beyond ERYTECH's control. There can be no guarantees with respect
to pipeline product candidates that the candidates will receive the
necessary regulatory approvals or that they will prove to be commercially
successful. Therefore, actual results may turn out to be materially
different from the anticipated future results, performance or achievements
expressed or implied by such statements, forecasts and estimates. Documents
filed by ERYTECH Pharma with the French Autorité des Marchés Financiers
(www.amf-france.org), also available on ERYTECH's website (www.erytech.com)
describe such risks and uncertainties. Given these uncertainties, no
representations are made as to the accuracy or fairness of such forward-
looking statements, forecasts and estimates. Furthermore, forward-looking
statements, forecasts and estimates only speak as of the date of the
publication of this document. Readers are cautioned not to place undue
reliance on any of these forward-looking statements. ERYTECH disclaims any
obligation to update any such forward-looking statement, forecast or
estimates to reflect any change in ERYTECH's expectations with regard
thereto, or any change in events, conditions or circumstances on which any
such statement, forecast or estimate is based, except to the extent
required by law.


---------------------------------------------------------------------------

26.09.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

505389 26.09.2016